KKK

KREBS BIOCHEM&INDS

No trades
See on Supercharts
Market capitalization
‪1.41 B‬INR
−9.15INR
‪−197.28 M‬INR
‪504.22 M‬INR
Beta (1Y)
0.25

About KREBS BIOCHEM&INDS

CEO
Jitendra Shah
Headquarters
Hyderabad
Founded
1991
ISIN
INE268B01013
FIGI
BBG000DC0HZ2
Krebs Biochemicals & Industries Ltd. engages in the manufacture and sale of pharmaceutical ingredients and intermediates. Its products include Androstenedione, Lovastatin, and Simvastatin. The company was founded by Ravindranath Tagore Ravi on December 2, 1991 and is headquartered in Hyderabad, India.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of KREBSBIO is 64.55 INR — it has decreased by 0.92% in the past 24 hours. Watch KREBS BIOCHEM&INDS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange KREBS BIOCHEM&INDS stocks are traded under the ticker KREBSBIO.
KREBSBIO stock has fallen by 6.04% compared to the previous week, the month change is a 11.58% fall, over the last year KREBS BIOCHEM&INDS has showed a 3.61% increase.
KREBSBIO reached its all-time high on Mar 11, 1999 with the price of 253.00 INR, and its all-time low was 50.65 INR and was reached on Mar 29, 2023. View more price dynamics on KREBSBIO chart.
See other stocks reaching their highest and lowest prices.
KREBSBIO stock is 4.68% volatile and has beta coefficient of 0.25. Track KREBS BIOCHEM&INDS stock price on the chart and check out the list of the most volatile stocks — is KREBS BIOCHEM&INDS there?
Today KREBS BIOCHEM&INDS has the market capitalization of ‪1.41 B‬, it has decreased by 3.37% over the last week.
Yes, you can track KREBS BIOCHEM&INDS financials in yearly and quarterly reports right on TradingView.
KREBSBIO net income for the last quarter is ‪−58.47 M‬ INR, while the quarter before that showed ‪−49.77 M‬ INR of net income which accounts for −17.47% change. Track more KREBS BIOCHEM&INDS financial stats to get the full picture.
No, KREBSBIO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. KREBS BIOCHEM&INDS EBITDA is ‪−87.24 M‬ INR, and current EBITDA margin is −17.30%. See more stats in KREBS BIOCHEM&INDS financial statements.
Like other stocks, KREBSBIO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade KREBS BIOCHEM&INDS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So KREBS BIOCHEM&INDS technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating KREBS BIOCHEM&INDS stock shows the sell signal. See more of KREBS BIOCHEM&INDS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.